Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model
- PMID: 23877104
- DOI: 10.2133/dmpk.dmpk-13-rg-058
Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model
Abstract
The aim of this study was to examine whether organic cation/carnitine transporter 2 (OCTN2/SLC22A5) plays a role in the human blood-brain barrier (BBB) by evaluating its functional activity in human brain endothelial cells (hCMEC/D3), which are considered to be a model of the BBB. The uptake of [(3)H]L-carnitine by hCMEC/D3 cells was time-, extracellular sodium- and concentration-dependent, with a Km value of 15.7 µM. These results are consistent with the properties of OCTN2-mediated L-carnitine transport. hCMEC/D3 cells showed relatively high expression of OCTN2 mRNA, and this expression was effectively decreased at 24-72 h after lipofection of cells with OCTN2 siRNA under optimized conditions. [(3)H]L-Carnitine uptake was dramatically suppressed by silencing of the OCTN2 gene. The inhibitory effect of OCTN2 gene silencing was similar to that of an excess amount of unlabeled L-carnitine. These results indicate that OCTN2 is involved in L-carnitine transport at the human BBB.
Similar articles
-
Memantine transport by a proton-coupled organic cation antiporter in hCMEC/D3 cells, an in vitro human blood-brain barrier model.Drug Metab Pharmacokinet. 2015 Apr;30(2):182-7. doi: 10.1016/j.dmpk.2014.12.006. Epub 2015 Jan 2. Drug Metab Pharmacokinet. 2015. PMID: 25857234
-
Molecular cloning and functional characterization of the OCTN2 transporter at the RBE4 cells, an in vitro model of the blood-brain barrier.Brain Res. 2003 Apr 4;968(1):69-79. doi: 10.1016/s0006-8993(02)04271-3. Brain Res. 2003. PMID: 12644265
-
Chronic liver injury decreases levels of cerebral carnitine and acetylcarnitine in rats partly due to the downregulation of organic cation transporters OCT1/2 and OCTN2 at the blood-brain barrier.Drug Metab Dispos. 2025 May;53(5):100072. doi: 10.1016/j.dmd.2025.100072. Epub 2025 Mar 27. Drug Metab Dispos. 2025. PMID: 40300306
-
Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5).Expert Opin Ther Targets. 2018 Aug;22(8):715-726. doi: 10.1080/14728222.2018.1502273. Epub 2018 Jul 23. Expert Opin Ther Targets. 2018. PMID: 30016594 Review.
-
Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21).Biopharm Drug Dispos. 2013 Jan;34(1):29-44. doi: 10.1002/bdd.1816. Epub 2012 Oct 14. Biopharm Drug Dispos. 2013. PMID: 22952014 Review.
Cited by
-
Organic Cation Transporter (OCT/OCTN) Expression at Brain Barrier Sites: Focus on CNS Drug Delivery.Handb Exp Pharmacol. 2021;266:301-328. doi: 10.1007/164_2021_448. Handb Exp Pharmacol. 2021. PMID: 33674914 Free PMC article.
-
Solute Carriers in the Blood-Brain Barier: Safety in Abundance.Neurochem Res. 2017 Mar;42(3):795-809. doi: 10.1007/s11064-016-2030-x. Epub 2016 Aug 9. Neurochem Res. 2017. PMID: 27503090 Review.
-
Reduced L-carnitine transport in aortic endothelial cells from spontaneously hypertensive rats.PLoS One. 2014 Feb 28;9(2):e90339. doi: 10.1371/journal.pone.0090339. eCollection 2014. PLoS One. 2014. PMID: 24587332 Free PMC article.
-
Unraveling the metabolomic architecture of autism in a large Danish population-based cohort.BMC Med. 2024 Jul 19;22(1):302. doi: 10.1186/s12916-024-03516-7. BMC Med. 2024. PMID: 39026322 Free PMC article.
-
In Vitro Methodologies to Study the Role of Advanced Glycation End Products (AGEs) in Neurodegeneration.Nutrients. 2022 Jan 15;14(2):363. doi: 10.3390/nu14020363. Nutrients. 2022. PMID: 35057544 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases